Biotech Values

[genisi]

The '893 COM patent expires March 2010 and is under re-examination.
The '995 COM patent for the atorvastatin enantiomer expires June 2011, but is under review with the USPTO, awaiting re-issuance. Failing to resolve this patent would result in the March 2010 patent expiration.
The rest of atorvastatin patents for formulation, crystal structure, and method-of-use expire in 2013-2017.